相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity
Ariella B. Hanker et al.
CANCER CELL (2021)
Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer
Lillian M. Smyth et al.
CANCER DISCOVERY (2020)
Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial
Nicholas C Turner et al.
LANCET ONCOLOGY (2020)
TargetableERBB2mutation status is an independent marker of adverse prognosis in estrogen receptor positive,ERBB2non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets
Sasagu Kurozumi et al.
BREAST CANCER RESEARCH (2020)
Neratinib plus trastuzumab plus fulvestrant for HER2-mutant, hormone receptor-positive, metastatic breast cancer: Updated results from the phase 2 SUMMIT 'basket' trial
Hans Wildiers et al.
CANCER RESEARCH (2020)
HER2-L755S mutation induces hyperactive MAPK and PI3K-mTOR signaling, leading to resistance to HER2 tyrosine kinase inhibitor treatment
Jiayao Li et al.
CELL CYCLE (2019)
Genomic characterization of metastatic breast cancers
Francois Bertucci et al.
NATURE (2019)
Neratinib in Combination With Trastuzumab for the Treatment of Patients With Advanced HER2-positive Breast Cancer: A Phase I/II Study
Kimberly L. Blackwell et al.
CLINICAL BREAST CANCER (2019)
Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer
Sarah Croessmann et al.
CLINICAL CANCER RESEARCH (2019)
Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies
Utthara Nayar et al.
NATURE GENETICS (2019)
Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer
Arielle J. Medford et al.
NPJ PRECISION ONCOLOGY (2019)
High-Throughput Functional Evaluation of Variants of Unknown Significance in ERBB2
Masaaki Nagano et al.
CLINICAL CANCER RESEARCH (2018)
The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers
Pedram Razavi et al.
CANCER CELL (2018)
HER kinase inhibition in patients with HER2-and HER3-mutant cancers
David M. Hyman et al.
NATURE (2018)
Drifts in ADCC-related quality attributes of Herceptin®: Impact on development of a trastuzumab biosimilar
Seokkyun Kim et al.
MABS (2017)
An Acquired HER2T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer
Ariella B. Hanker et al.
CANCER DISCOVERY (2017)
AACR Project GENIE: Powering Precision Medicine through an International Consortium
Fabrice Andre et al.
CANCER DISCOVERY (2017)
Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer
Cynthia X. Ma et al.
CLINICAL CANCER RESEARCH (2017)
Genomic Characterization of Primary Invasive Lobular Breast Cancer
Christine Desmedt et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Trastuzumab-induced recruitment of Csk-homologous kinase (CHK) to ErbB2 receptor is associated with ErbB2-Y1248 phosphorylation and ErbB2 degradation to mediate cell growth inhibition
Milos Dokmanovic et al.
CANCER BIOLOGY & THERAPY (2014)
Dual HER2 blockade: preclinical and clinical data
Tejal A. Patel et al.
BREAST CANCER RESEARCH (2014)
Relapsed Classic E-Cadherin (CDH1)-Mutated Invasive Lobular Breast Cancer Shows a High Frequency of HER2 (ERBB2) Gene Mutations
Jeffrey S. Ross et al.
CLINICAL CANCER RESEARCH (2013)
Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer
Ron Bose et al.
CANCER DISCOVERY (2013)
Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer
Alexandra Canonici et al.
ONCOTARGET (2013)
HER2 Phosphorylation Is Maintained by a PKB Negative Feedback Loop in Response to Anti-HER2 Herceptin in Breast Cancer
Merel Gijsen et al.
PLOS BIOLOGY (2010)
Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941
Teemu T. Junttila et al.
CANCER CELL (2009)
Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity
M. Scaltriti et al.
ONCOGENE (2009)
分享论文
